Search Clinical Trials in the EU

Duration

Visits

Phase

Oral

Benefits

Drugs

Locations

Clinical Specialty

61-80 of 1,694 trials

Diffuse Large B-Cell Lymphoma: Acalabrutinib with R-miniCHOP

We are studying whether adding acalabrutinib to a reduced chemotherapy regimen helps older adults with untreated diffuse large B-cell lymphoma live longer and have better treatment responses. This trial is for those over 60 or 80 years who cannot receive full-dose chemotherapy.

High-Grade B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visits No Placebo Standard MedicinesHematologyOncology

Advanced Solid Tumors: REGN7075 with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining REGN7075 and cemiplimab for patients with advanced cancers. This trial aims to explore how well this combination works and its impact on patients' quality of life.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No Placebo Investigational Medicines Partially RemoteOncology

Heart Failure in Children: Vericiguat Study

We are studying a new medication, vericiguat, to see if it helps improve heart function in children with heart failure. The trial compares its effects to a placebo to ensure safety and effectiveness.

Chronic Systolic Heart FailureEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteCardiologyPediatrics

Cancer Treatment: Long-term Study of Pembrolizumab

We are evaluating the long-term safety and survival of patients currently on pembrolizumab treatment. This study aims to understand how well the treatment works and its effects over time.

Advanced Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Brexucabtagene Autoleucel for Rare B-cell Malignancies

We are studying a new treatment for adults with relapsed or refractory Richter Transformation of B-cell malignancies. The goal is to see if it improves response rates and overall survival compared to existing options.

Relapsed/Refractory Richter Transformation1-2 yearsEfficacy phase (II)6-10 visits No Placebo Standard Medicines Partially RemoteHematologyOncology

Colorectal Cancer: UNICORN Study on Targeted Preoperative Treatments

We are studying short-course targeted treatments for patients with resectable colorectal cancer to see if they improve treatment response and quality of life. This trial aims to understand the safety and effectiveness of these treatments before surgery.

Colorectal Adenocarcinoma1-2 yearsEfficacy phase (II)No Placebo Investigational MedicinesOncology

Multiple Sclerosis: Ozanimod vs. Fingolimod

We are studying whether the new medication ozanimod is more effective and safe than fingolimod for children and adolescents with relapsing remitting multiple sclerosis. This trial will also assess how the body handles ozanimod.

Relapsing-Remitting Multiple SclerosisConfirmation phase (III)Post-Trial Drug Access No Placebo Standard MedicinesNeurology

Axial Spondyloarthritis: Filgotinib Study

We are testing the medication filgotinib in adults with active axial spondyloarthritis to see if it improves symptoms and physical function compared to a placebo. The study also looks at the safety of this treatment.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)11-15 visits Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Acute Myeloid Leukemia: Oral-Azacitidine with Gilteritinib

We are studying a new combination treatment for adults with relapsed or refractory FLT3-mutated acute myeloid leukemia. The goal is to see if this approach improves remission rates and safety compared to current options.

Acute Myeloid Leukaemia>2 yearsEfficacy phase (II)6-10 visits No Placebo Standard MedicinesHematologyOncology

COVID-19 Treatment: Antiviral Therapy for Immunocompromised Patients

We are studying a combination of antiviral medications to see if it helps immunocompromised patients recover from COVID-19 more effectively. The goal is to improve viral clearance and reduce symptoms compared to standard treatments.

Covid-193-6 monthsEfficacy phase (II)≤5 visits No Placebo Standard Medicines Partially RemoteInfectious DiseasesInternal Medicine

Cognitive Deficits in Multiple Sclerosis: MODAFIMS Study

We are studying the effects of modafinil on cognitive deficits in people with Multiple Sclerosis. The trial aims to identify brain features that may predict treatment response and assess changes in cognitive function and quality of life.

Multiple Sclerosis6-12 monthsEfficacy phase (II)≤5 visits No Placebo Standard MedicinesNeurology

Heart Attack Recovery: Milvexian Study

We are testing a new oral medication, milvexian, to see if it helps reduce the risk of further heart problems in patients after a heart attack. This study compares milvexian to a placebo alongside standard treatment.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

NonAdvanced Systemic Mastocytosis: Bezuclastinib Study

We are testing a new oral medication, bezuclastinib, to see if it is effective and safe for patients with NonAdvanced Systemic Mastocytosis. This study compares the medication to a placebo to understand its potential benefits.

Systemic Mastocytosis6-12 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyHematology

Dexamethasone for Moderate to Severe Depression

We are studying whether adding dexamethasone to standard depression treatment can improve symptoms for those with moderate to severe depression. This trial aims to assess its safety and effectiveness.

Depression6-12 monthsConfirmation phase (III)≤5 visits Investigational Medicines Cost Reimbursement Partially RemotePsychiatry

Breast Cancer: Elacestrant vs. Standard Therapy

We are studying whether elacestrant can help women with ER+/HER2- breast cancer who have signs of relapse delay cancer spread compared to standard treatments. The trial also looks at safety and how patients feel about the treatment.

Breast Cancer>2 yearsConfirmation phase (III)No Placebo Standard MedicinesOncology

Atopic Dermatitis: Lebrikizumab for Kids

We are studying a new treatment for children and teens with moderate-to-severe atopic dermatitis. The goal is to see if it works better than a placebo when used alongside standard treatments.

Atopic Dermatitis (Eczema)3-6 monthsConfirmation phase (III)Post-Trial Drug Access Investigational MedicinesDermatology

Hypertension in Chronic Kidney Disease: Diuretic Treatment Study

We are investigating if a new diuretic-based treatment helps people with moderate to severe chronic kidney disease and uncontrolled hypertension. The goal is to see if it can reduce serious health issues like kidney failure and heart problems.

Chronic Kidney DiseaseUncontrolled Hypertension>2 yearsConfirmation phase (III)6-10 visits No Placebo Standard MedicinesCardiologyNephrology

HER2-positive Breast Cancer: Trastuzumab Deruxtecan Study

We are comparing a new treatment with standard therapy for patients with HER2-positive breast cancer. The goal is to see which approach leads to better outcomes and to understand the effects on quality of life.

HER2 Positive Breast Cancer3-6 monthsEfficacy phase (II)No Placebo Investigational MedicinesOncology

Multiple Myeloma: Iberdomide vs. Lenalidomide Maintenance Therapy

We are comparing two treatments for newly diagnosed multiple myeloma patients after stem cell transplant to see which one may help keep the disease from worsening. This study will also look at safety and quality of life for participants.

Newly Diagnosed Multiple Myeloma>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHematologyOncology

Prostate Cancer: Surgery with Darolutamide

We are studying whether adding darolutamide before and after surgery helps improve survival and quality of life for patients with high-risk or locally advanced prostate cancer.

Prostate Cancer>2 yearsEfficacy phase (II)≤5 visits No Placebo Investigational MedicinesOncologyUrology

Search Clinical Trials in the European Union